论文部分内容阅读
目的:通过检测EDD和MRP2蛋白在上皮性卵巢癌中的表达,探讨其与上皮性卵巢癌发生发展关系及其临床意义。方法:收集中山大学肿瘤防治中心1997-05-1-2003-12-31存档的上皮性卵巢癌术后组织石蜡标本72例、良性上皮性卵巢肿瘤组织石蜡标本15例和正常卵巢组织石蜡标本10例。应用免疫组化SP法检测EDD和MRP2蛋白在卵巢癌组织中的表达,并结合临床病理因素和预后进行分析。结果:EDD和MRP2蛋白在上皮性卵巢癌中的表达率分别为94.4%和54.2%,与正常卵巢组织和良性卵巢肿瘤相比,差异有统计学意义。EDD弱阳性表达的患者化疗有效率20.8%,EDD强阳性表达的患者化疗有效率65.9%,两组化疗缓解率差异无统计学意义,P=0.252。MRP2表达阴性的患者化疗缓解率为84.8%,MRP2表达阳性的患者化疗缓解率为59.0%,阴性表达组的化疗缓解率明显高于阳性表达组,P=0.016。结论:EDD蛋白的过度表达可能与上皮性卵巢癌的发生相关;MRP2蛋白在上皮性卵巢癌中的表达可能与肿瘤细胞固有的耐药相关,它在上皮性卵巢癌中的过度表达可能引起化疗耐药。
OBJECTIVE: To investigate the relationship between the expression of EDD and MRP2 in epithelial ovarian cancer and its clinical significance with the development of epithelial ovarian cancer. Methods: 72 cases of postoperative paraffin-embedded specimens of epithelial ovarian cancer, 15 cases of benign epithelial ovarian tumor and 15 cases of normal ovarian tissue paraffin-embedded specimens from Cancer Center of Sun Yat-sen University were collected. example. Immunohistochemical SP method was used to detect the expression of EDD and MRP2 protein in ovarian cancer tissues, and combined with clinicopathological factors and prognosis. Results: The expression rates of EDD and MRP2 in epithelial ovarian cancer were 94.4% and 54.2%, respectively, which were significantly different from those in normal ovarian tissues and benign ovarian tumors. The effective rate of chemotherapy was 20.8% in patients with weak positive expression of EDD, and 65.9% in patients with strong positive expression of EDD. There was no significant difference in the response rate between two groups (P = 0.252). Chemotherapy response rate was 84.8% in MRP2-negative patients, 59.0% in MRP2-positive patients, and was significantly higher in negative patients than in positive ones (P = 0.016). Conclusion: The overexpression of EDD protein may be related to the occurrence of epithelial ovarian cancer. The expression of MRP2 protein in epithelial ovarian cancer may be related to the intrinsic drug resistance of tumor cells. Its overexpression in epithelial ovarian cancer may lead to chemotherapy Resistance.